Cite
Lee FC, Harris W, Cheng HH, et al. Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. Adv Urol. 2013;2013:317190doi: 10.1155/2013/317190.
Lee, F. C., Harris, W., Cheng, H. H., Shenoi, J., Zhao, S., Wang, J., Champion, T., Izard, J., Gore, J. L., Porter, M., Yu, E. Y., & Wright, J. L. (2013). Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. Advances in urology, 2013317190. https://doi.org/10.1155/2013/317190
Lee, Franklin C, et al. "Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer." Advances in urology vol. 2013 (2013): 317190. doi: https://doi.org/10.1155/2013/317190
Lee FC, Harris W, Cheng HH, Shenoi J, Zhao S, Wang J, Champion T, Izard J, Gore JL, Porter M, Yu EY, Wright JL. Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. Adv Urol. 2013;2013:317190. doi: 10.1155/2013/317190. Epub 2013 Dec 08. PMID: 24382958; PMCID: PMC3871504.
Copy
Download .nbib